Comparative Pharmacology
Head-to-head clinical analysis: KADIAN versus XTAMPZA ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADIAN versus XTAMPZA ER.
KADIAN vs XTAMPZA ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
Oxycodone is a full mu-opioid receptor agonist, producing analgesia, euphoria, and sedation. Xtampza ER utilizes DETERx technology to provide extended-release properties and resist tampering.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
Initial: 9 mg orally every 12 hours with food; titrate by 9 mg every 3-7 days as needed; maximum dose: 36 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
3-4 hours for immediate-release morphine; 8-12 hours for extended-release formulation (XTAMPZA ER), allowing twice-daily dosing
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Primarily renal (70-90% as morphine-3-glucuronide, morphine-6-glucuronide, and free morphine); biliary/fecal (10-20%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic